PETACC-3试验:5-氟尿嘧啶/亚叶酸钙/伊立替康毒性的临床与药物遗传学决定因素
基于PETACC-3试验数据,分析2982例结直肠癌辅助化疗患者的临床与毒性数据,其中1200例有DNA样本。研究发现UGT1A1*28基因型与III-IV级中性粒细胞减少风险增加相关,但性别、年龄、体能状态等临床因素预测作用更强。
要点
- UGT1A1*28基因型与III-IV级中性粒细胞减少发生率升高相关。
- 性别、年龄、体能状态等临床因素比UGT1A1*28基因型对毒性的预测作用更强。
- 腹泻的主要预测因素为性别和年龄。
核心结论
- 毒性风险涉及包括UGT1A1在内的复杂因素组合,临床实践中易获取的参数(性别、年龄、体能状态)是比UGT1A1*28基因型更强的预测因素。
研究设计与样本
- 基于PETACC-3随机对照试验的回顾性分析,纳入2982例接受辅助化疗的结直肠癌患者,其中1200例(40%)有DNA样本用于UGT1A1*28和UGT1A1-3156G>A基因分型。
主要发现
- 单变量分析中,UGT1A*28基因型与III-IV级中性粒细胞减少发生率升高相关(发生率44% vs 26%;OR 2.3;95%CI 1.4-3.7)。
- 多变量分析中,中性粒细胞减少的最重要预测因素依次为基线中性粒细胞计数(每降低1单位(10^9/l)OR 1.8,95%CI 1.3-1.7)、女性(OR 1.8,95%CI 1.1-3.0)、体表面积(每增加0.1单位OR 0.8,95%CI 0.7-1.0)、UGT1A1(OR 2.8,95%CI 1.6-5.0)、年龄(每增加10岁OR 1.3,95%CI 1.1-1.6)和体能状态差(OR 1.6,95%CI 1.0-2.6)。
- IV级中性粒细胞减少的主要预测因素为性别、年龄、体能状态评分和UGT1A1;腹泻的主要预测因素为性别和年龄。
临床怎么用
- 在临床实践中,评估伊立替康联合5-FU/LV方案的毒性风险时,应综合考虑性别、年龄、体能状态、基线中性粒细胞计数、体表面积及UGT1A1*28基因型。
局限性
- 仅40%的患者有DNA样本可用于基因分型,可能影响遗传学分析的代表性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Irinotecan (CPT-11) in combination with 5-fluorouracil (5FU) is widely used in the treatment of colorectal cancer. We assessed potential clinical variables that may predict toxicity and more specifically the role of UGT1A1 polymorphisms associated with irinotecan toxicity. We used data from the PETACC3 trial, which randomised patients in adjuvant setting to 6 months of leucovorin (LV) and 5FU (LV5/FU2) or LV5/FU2 + irinotecan. PATIENTS AND METHODS: Clinical and toxicity data were available for 2982 patients, DNA was available for 1200 (40%) of these patients. We genotyped the polymorphisms UGT1A1*28 and UGT1A1-3156G > A. Risk factors for neutropenia and diarrhoea were assessed by univariable and multivariable analyses. RESULTS: In univariable analysis, UGT1A*28 genotype was associated with an increased incidence of grade III-IV neutropenia (incidence: 44% versus 26%; odds ratio [OR]: 2.3; 95% confidence interval [CI]: 1.4-3.7). In multivariable analysis, the most important predictors (ordered in terms of contribution to R2) were baseline neutrophil count (OR for 1-unit (109/l) decrease: 1.8, 95% CI: 1.3-1.7), female sex (OR: 1.8, 95% CI: 1.1-3.0), body surface area (OR for 0.1-unit increase: 0.8, 95% CI: 0.7-1.0), UGT1A1 (OR: 2.8, 95% CI: 1.6-5.0), age (OR per 10 years: 1.3, 95% CI: 1.1-1.6) and poor performance status (OR: 1.6, 95% CI: 1.0-2.6). The main predictors for grade IV neutropenia were sex, age, performance score and UGT1A1. The main predictors for diarrhoea were sex and age. CONCLUSIONS: We found that a complex of risk factors is involved in the development of toxicity, including UGT1A1. Parameters that are readily available in clinical practice, notably sex, age and performance status, are stronger predictors than the UGT1A1*28 genotype. Further studies beyond the UGT1A1*28 genotype are needed to fully understand the determinants of toxicity risk, notably in females.
引用
- Tejpar S, Yan P, Piessevaux H, et al. Clinical and pharmacogenetic determinants of 5-fluorouracyl/leucovorin/irinotecan toxicity: Results of the PETACC-3 trial. Eur J Cancer. 2018. PMID: 29909091. doi:10.1016/j.ejca.2018.05.009
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。